‘B3-MED’ has developed a digital platform for diagnosis and treatment of oncological diseases

‘B3-MED’ has developed a digital platform that allows seamless processing of information about the current stage of the diagnostic or treatment process in oncology, including complex methods of molecular diagnostics.

The system allows, based on the algorithms of a large array of data from current scientific research, to prioritize the treatment, to choose the best regimen of targeted drugs to achieve the best result in the treatment of oncological diseases.

At the same time, the user-friendly interface built into the medical information systems of clinics saves the doctor’s time for making correct clinical decisions, as well as allows to quickly implement innovative diagnostic and treatment approaches in oncology.

Thanks to the new B3-MED product, cancer treatment will become more effective and accessible for Russian citizens.

For example, molecular genetic testing allows the selection of personalized targeted therapy for cancer diseases. At the same time, it is included in the OMC, but the coverage of the diagnostic procedure in Russia is only 20%.

In addition, screening of hereditary oncologic diseases, especially among the young population, will be more accessible. This will make it possible to offer targeted individual dispensary programs, detect oncopathology at early stages and start treatment at early stages.